Efficacy and Safety of IVIG-L in ITP Patients
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Registration Number
- NCT00151840
- Lead Sponsor
- Prothya Biosolutions
- Brief Summary
The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature.
- Detailed Description
Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service (FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of intravenous immunoglobulin simplifies infusion, eliminates possible mistakes in the reconstitution with water for injection and reduces space requirements in storage.
In addition to donor selection and screening, several procedures have been included in the production process to improve viral safety.
In this clinical trial, the efficacy and safety of IVIG-L in patients with ITP will be assessed and compared with data obtained from literature. IVIG-L will also be studied in patients with hypogammaglobulinemia.The results from both studies will be used for an application for marketing authorisation of IVIG-L in Finland and the Netherlands.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Patients with chronic ITP with a platelet count of about 20x109/L and at high risk of bleeding
- Patients with chronic ITP with a platelet count of about 20x109/L, who have to undergo surgery
- A stable clinical situation (no activity of any other disease)
- Age at least 18 yrs
- The patient/legally acceptable representative has signed the consent form
- The presence of another autoimmune disease related with thrombocytopenia such as systematic lupus erythematosus (SLE), rheumatoid arthritis (RA) or nephritis
- Patients with drug-induced thrombocytopenia or immunologic thrombocytopenia of infectious origin (in particular, Hepatitis, Epstein-Barr virus, Toxoplasma, HIV)
- Massive splenomegaly
- Treatment with any other investigational drug within 7 days before study entry or previous enrolment in this study
- Having an ongoing progressive terminal disease, including HIV infection
- Known with allergic reactions against human plasma, plasma products or intravenous immunoglobulin
- Presence of conditions predisposing for bleeding: anaemia (hemoglobin < 5.5 mmol/L), renal or urogenital disease, malignant disease (with the exception of basalioma, cervix carcinoma in situ), history of intracranial or aortic aneurysm, stroke, oeso-gastro-intestinal disorders with a bleeding potential, severe hypertension (diastole > 110 mm Hg).
- Use of corticosteroids for an acute situation within 7 days before study entry. Patients using corticosteroids prophylactically can be included
- Splenectomy in the previous two weeks
- Renal insufficiency (plasma creatinine > 115µmol/L)
- Pregnancy or lactation
- Known with insufficiency of coronary or cerebral circulation
- IgA deficiency and anti-IgA antibodies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method The efficacy of IVIG-L The safety of IVIG-L
- Secondary Outcome Measures
Name Time Method To compare data on efficacy and safety of IVIG-L with data obtained from literature
Trial Locations
- Locations (6)
Hematology Clinic, Medical University of Bialystok
🇵🇱Bialystok, Poland
Clinic of Haematology, Medical University of Lodz
🇵🇱Lodz, Poland
Institute of Haematology and Transfusiology
🇵🇱Warsaw, Poland
Haematology Clinic, Medical University of Gdansk
🇵🇱Gdansk, Poland
Clinical of Internal Diseases and haematology with Bone marrow Transplantation Unit, Central Academic Hospital, Medical Military Academy
🇵🇱Warsaw, Poland
Haematology Clinic, Medical University of Warsaw
🇵🇱Warsaw, Poland